Oricell said its GPC3-targeted autologous CAR T therapy, Ori-C101, is moving into a confirmatory registration Phase II trial for patients with GPC3-positive advanced hepatocellular carcinoma. The company frames this as the first GPC3-directed immune cell therapy and the first CAR T program for liver cancer to reach the confirmatory registration phase, aiming to establish a pivotal evidence package. If the program supports registration pathways, it could expand the liver oncology cell-therapy toolbox beyond conventional systemic approaches and broaden target validation for glypican-3 in an immunologically challenging tumor environment.